Abstract
Passive immunization studies in non-human primates have established unequivocally that virus neutralization can prevent infection, providing the impetus for current intense efforts to identify immunogens that elicit broadly neutralizing antibodies in humans. Although Fc-mediated effector function may also contribute to protection by neutralizing antibodies, its role in protection by non-neutralizing antibodies is controversial. Here, I review the literature suggesting a role for Fc-mediated effector by non-neutralizing antibodies in protective immunity against HIV-1 with a primary focus on antibody mediated cellular cytotoxicity (ADCC) and related responses such as antibody-dependent cellular viral inhibition (ADCVI). Special emphasis is placed on qualitative and quantitative variables including antibody specificity and dose-response behavior in vitro and in vivo, which I propose as key variables in future passive immunization studies. Properly configured, these studies should clarify the role of Fc-mediated effector function by nonneutralizing antibodies in protection against HIV-1.
Keywords: Antibody-dependent cell mediated cytotoxicity, antibody structure, antigen structure, Fc-mediated effector function.
Current HIV Research
Title:Qualitative and Quantitative Variables that Affect the Potency of Fc- Mediated Effector Function In Vitro and In Vivo: Considerations for Passive Immunization Using Non-Neutralizing Antibodies
Volume: 11 Issue: 5
Author(s): George K Lewis
Affiliation:
Keywords: Antibody-dependent cell mediated cytotoxicity, antibody structure, antigen structure, Fc-mediated effector function.
Abstract: Passive immunization studies in non-human primates have established unequivocally that virus neutralization can prevent infection, providing the impetus for current intense efforts to identify immunogens that elicit broadly neutralizing antibodies in humans. Although Fc-mediated effector function may also contribute to protection by neutralizing antibodies, its role in protection by non-neutralizing antibodies is controversial. Here, I review the literature suggesting a role for Fc-mediated effector by non-neutralizing antibodies in protective immunity against HIV-1 with a primary focus on antibody mediated cellular cytotoxicity (ADCC) and related responses such as antibody-dependent cellular viral inhibition (ADCVI). Special emphasis is placed on qualitative and quantitative variables including antibody specificity and dose-response behavior in vitro and in vivo, which I propose as key variables in future passive immunization studies. Properly configured, these studies should clarify the role of Fc-mediated effector function by nonneutralizing antibodies in protection against HIV-1.
Export Options
About this article
Cite this article as:
Lewis K George, Qualitative and Quantitative Variables that Affect the Potency of Fc- Mediated Effector Function In Vitro and In Vivo: Considerations for Passive Immunization Using Non-Neutralizing Antibodies, Current HIV Research 2013; 11 (5) . https://dx.doi.org/10.2174/1570162X113116660060
DOI https://dx.doi.org/10.2174/1570162X113116660060 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cationic Liposomes as In Vivo Delivery Vehicles
Current Medicinal Chemistry The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Infectious Co-Factors in HIV-1 Transmission Herpes Simplex Virus Type-2 and HIV-1: New Insights and Interventions
Current HIV Research Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Appropriate Use of Antibiotics for the Management of Respiratory Tract Infections
Infectious Disorders - Drug Targets Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Chitosan and Gelatin based Prototype Delivery Systems for the Treatment of Oral Mucositis: from Material to Performance in vitro
Current Drug Delivery Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design The Effects of Soy Isoflavones in Postmenopausal Women: Clinical Review
Current Drug Therapy Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Molecular Actions of Polyhalogenated Arylhydrocarbons (PAHs) in Female Reproduction
Current Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Alternative Chitosan Based Drug Delivery System to Fight Oral Mucositis: Synergy of Conventional and Bioactives Towards the Optimal Solution
Current Nanoscience Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Recent Advances in the Discovery of Novel Anti-Herpetic Agents from Chinese Herbal Medicines
Current Organic Chemistry Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Chitosan and Its Use in Design of Insulin Delivery System
Recent Patents on Drug Delivery & Formulation Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2/M Phase
Anti-Cancer Agents in Medicinal Chemistry The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine